Patents by Inventor Shiro Akinaga
Shiro Akinaga has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9757344Abstract: A coated fine particle comprisisng: (i) a complex of a drug and a cationic lipid, wherein (a) the drug is a nucleic acid and the complex is obtained by mixing the drug and the cationic lipid in water, wherein the complex has a diameter of 10 nm to 1,000 nm, and (ii) a lipid layer formed of lipid(s), wherein the lipid(s) is selected from phospholipid, glyceroglycolipid, sphingoglycolipid, cholesterol and synthetic lipid, wherein the complex is coated with the lipid layer.Type: GrantFiled: February 1, 2010Date of Patent: September 12, 2017Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Yasuki Kato, Masahiro Yamauchi, Hiroko Kusano, Takeshi Iwata, Takaaki Uochi, Shiro Akinaga
-
Patent number: 9675625Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: GrantFiled: June 17, 2013Date of Patent: June 13, 2017Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Rinpei Niwa, So Ohta, Yuka Sakai, Junji Kanazawa, Toshihiko Ishii, Shiro Akinaga
-
Publication number: 20150265545Abstract: A method for coating fine particles with lipid membrane, characterized in that, the rate of a polar organic solvent in an aqueous solution containing the polar organic solvent where the fine particles are dispersed and lipid is dissolved, is decreased.Type: ApplicationFiled: April 10, 2015Publication date: September 24, 2015Inventors: Yasuki KATO, Masahiro YAMAUCHI, Hiroko KUSANO, Takeshi IWATA, Takaaki UOCHI, Shiro AKINAGA
-
Publication number: 20130295045Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: ApplicationFiled: June 17, 2013Publication date: November 7, 2013Inventors: Kenya SHITARA, Rinpei NIWA, So OHTA, Yuka SASAKI, Junji KANAZAWA, Toshihiko ISHII, Shiro AKINAGA
-
Patent number: 8491902Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: GrantFiled: December 3, 2004Date of Patent: July 23, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Rinpei Niwa, So Ohta, Yuka Sasaki, Junji Kanazawa, Toshihiko Ishii, Shiro Akinaga
-
Publication number: 20120329794Abstract: The present invention provides an Abelson kinase (Abl kinase) inhibitor which comprises, as an active ingredient, an indazole derivative represented by Formula (I) (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group) or a pharmaceutically acceptable salt thereof, an Abl kinase inhibitor which comprises, as an active ingredient, an indazole derivative represented by Formula (Ia) [wherein R2 represents CONR4aR4b (wherein R4a and R4b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like, or R4a and R4b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like, and R3 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like] or a pharmaceutically acceptable salt thereof, and the like.Type: ApplicationFiled: June 29, 2007Publication date: December 27, 2012Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Yukimasa Shiotsu, Kenichi Ishii, Hiroshi Umehara, Shiro Akinaga
-
Publication number: 20120020962Abstract: The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering to a patient a monoclonal antibody which specifically binds to human CC chemokine 4 (CCR4) or the antibody fragment thereof.Type: ApplicationFiled: September 6, 2011Publication date: January 26, 2012Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Ryuzo UEDA, Kenya SHITARA, Shiro AKINAGA, Rinpei NIWA, Masamichi KOIKE
-
Patent number: 7767693Abstract: The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R3 and R5, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R4 and R6, which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.Type: GrantFiled: April 22, 2009Date of Patent: August 3, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Shinji Nara, Hiroshi Nakagawa, Yutaka Kanda, Takayuki Nakashima, Shiro Soga, Jiro Kajita, Jun-ichi Saito, Yukimasa Shiotsu, Shiro Akinaga
-
Publication number: 20100166847Abstract: An object of the present invention is to provide a safe, convenient and efficient method for coating fine particles with lipid membrane. There is provided a method for coating fine particles with lipid membrane, characterized in that, the rate of a polar organic solvent in an aqueous solution containing the polar organic solvent where the fine particles are dispersed and lipid is dissolved, is decreased.Type: ApplicationFiled: February 1, 2010Publication date: July 1, 2010Inventors: Yasuki Kato, Masahiro Yamauchi, Hiroko Kusano, Takeshi Iwata, Takaaki Uochi, Shiro Akinaga
-
Publication number: 20100150917Abstract: The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering to a patient a monoclonal antibody which specifically binds to human CC chemokine 4 (CCR4) or the antibody fragment thereof.Type: ApplicationFiled: October 5, 2009Publication date: June 17, 2010Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Ryuzo UEDA, Kenya Shitara, Shiro Akinaga, Rinpei Niwa, Masamichi Koike
-
Publication number: 20100098690Abstract: The present invention provides a pharmaceutical composition comprising a combination of an Hsp 90 family protein inhibitor and at least one compound, the said pharmaceutical composition wherein the Hsp 90 family protein inhibitor is a benozoyl compound represented by formula (I): [wherein n represents an integer of 1 to 5; R1 represents substituted or unsubstituted lower alkyl, CONR7R8 (wherein R7 and R8, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, or the like), or the like; R2 represents substituted or unsubstituted aryl, or the like; R3 and R5, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, or the like; R4 represents a hydrogen atom, hydroxy or halogen; and R6 represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like], or a prodrug thereof; or a pharmaceutically acceptable salt thereof, and the like.Type: ApplicationFiled: March 5, 2008Publication date: April 22, 2010Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Shiro Soga, Toshihiko Ishii, Takayuki Nakashima, Yukimasa Shiotsu, Shiro Akinaga
-
Patent number: 7678415Abstract: An object of the present invention is to provide a safe, convenient and efficient method for coating fine particles with lipid membrane. There is provided a method for coating fine particles with lipid membrane, characterized in that, the rate of a polar organic solvent in an aqueous solution containing the polar organic solvent where the fine particles are dispersed and lipid is dissolved, is decreased.Type: GrantFiled: October 4, 2001Date of Patent: March 16, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Yasuki Kato, Masahiro Yamauchi, Hiroko Kusano, Takeshi Iwata, Takaaki Uochi, Shiro Akinaga
-
Publication number: 20090247522Abstract: The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R3 and R5, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R4 and R6, which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.Type: ApplicationFiled: April 22, 2009Publication date: October 1, 2009Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Shinji Nara, Hiroshi Nakagawa, Yutaka Kanda, Takayuki Nakashima, Shiro Soga, Jiro Kajita, Jun-ichi Saito, Yukimasa Shiotsu, Shiro Akinaga
-
Patent number: 7547675Abstract: The present invention relates to a chemically modified polypeptide in which at least one of hydroxyl groups in the polypeptide molecule is modified with a polyalkylene glycol derivative; a method for producing the modified polypeptide; a method of treatment using the modified polypeptide; use of the modified polypeptide; a pharmaceutical preparation comprising the modified polypeptide; and a composition for treatment comprising the modified polypeptide.Type: GrantFiled: February 13, 2003Date of Patent: June 16, 2009Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Motoo Yamasaki, Toshiyuki Suzawa, Ken Kobayashi, Noboru Konishi, Shiro Akinaga, Kumiko Maruyama
-
Patent number: 7538224Abstract: The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R3 and R5, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R4 and R6, which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.Type: GrantFiled: June 10, 2004Date of Patent: May 26, 2009Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Shinji Nara, Hiroshi Nakagawa, Yutaka Kanda, Takayuki Nakashima, Shiro Soga, Jiro Kajita, Jun-ichi Saito, Yukimasa Shiotsu, Shiro Akinaga
-
Publication number: 20070172476Abstract: The present invention relates to a method for injuring or depleting a B-cell neoplasm cell or a Hodgkin's lymphoma cell and a method for treating B-cell neoplasm or Hodgkin's lymphoma, wherein each method comprises administering to a patient a monoclonal antibody which specifically binds to a human CC chemokine receptor 4 (CCR4) or an antibody fragment thereof.Type: ApplicationFiled: July 28, 2006Publication date: July 26, 2007Applicants: Kyowa Hakko Kogyo Co., Ltd., Board of Regents, The University of Texas SystemInventors: Ryuzo Ueda, Takashi Ishida, Shiro Akinaga, Toshihiko Ishii, Daniel Jones, Richard Ford, Jahan Khalili, Kaushali Patel
-
Publication number: 20070032532Abstract: The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; R1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; R3 and R5, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and R4 and R6, which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.Type: ApplicationFiled: June 10, 2004Publication date: February 8, 2007Applicant: Kyowa Hakko Kogyo Co., Ltd.Inventors: Shinji Nara, Hiroshi Nakagawa, Yutaka Kanda, Takayuki Nakashima, Shiro Soga, Jiro Kajita, Jun-ichi Saito, Yukimasa Shiotsu, Shiro Akinaga
-
Publication number: 20070020263Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: ApplicationFiled: December 3, 2004Publication date: January 25, 2007Inventors: Kenya Shitara, Rinpei Niwa, So Ohta, Yuka Sasaki, Junji Kanazawa, Toshihiko Ishii, Shiro Akinaga
-
Publication number: 20070004674Abstract: A medicament comprising a compound having an inhibitory action on Hsp90 or a pharmaceutically acceptable salt thereof as an active ingredient is used as a therapeutic agent for diseases associated with immunoglobulin gene translocations. In diseases associated with immunoglobulin gene translocations, abnormal enhancement of the expression of a partner gene in immunoglobulin gene translocation participates in the development of the diseases and the progress of the symptoms. By administering the compound having an inhibitory action on Hsp90 or a pharmaceutically acceptable salt thereof, degradation of protein encoded by the partner gene is promoted and the diseases can be treated.Type: ApplicationFiled: August 23, 2004Publication date: January 4, 2007Applicant: Kyowa Hakko Kogyo Co. Ltd.Inventors: Yukimasa Shiotsu, Shiro Soga, Yutaka Kanda, Shiro Akinaga
-
Publication number: 20060281789Abstract: The present invention provides a protein kinase inhibitor (excluding c-Jun N-terminal kinase inhibitor) which comprises, as an active ingredient, an indazole derivative represented by Formula (I) (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: July 30, 2004Publication date: December 14, 2006Applicant: KYOWA HAKKO KOGYO CO., LTDInventors: Yukimasa Shiotsu, Hiroshi Umehara, Fumihiko Kanai, Shinji Nara, Yoshihisa Ohta, Yutaka Kanda, Shiro Akinaga, Tomoki Naoe, Hitoshi Kiyoi, Tomoyuki Nakazato, Satoshi Tashiro